Literature DB >> 29143145

Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study.

J Khoury1, M Szwarcwort2, Z Kra-Oz2, M Saffuri3, K Seh3, T Yahalomi3, E Braun3,4, Z S Azzam1,3, M Paul3,5, A Neuberger6,7,8,9.   

Abstract

The purpose of this study was to determine the rate of decline in the diagnostic yield of influenza PCR assay after oseltamivir administration, and to identify risk factors for prolonged shedding. This was a prospective observational study. We included adult inpatients with clinical signs of influenza during the influenza seasons 2015 and 2016, who had positive influenza PCR tests and who were treated with oseltamivir. Clinical follow-up and repeat PCR testing were performed on days 2, 4 and 6 after the first positive test. We defined prolonged shedders as patients who still required hospitalization and had a positive PCR assay on day 4. Risk factors for prolonged shedding were assessed in univariate and multivariate analyses. A total of 215 patients were included in our study. The median age was 64 years and 49.3% were men. The main influenza type was H1N1 (50.1%). Rates of PCR positivity among evaluable patients on days 2, 4 and 6 were 142/215 (66%), 50/78 (64.1%) and 20/30 (66.6%), respectively. Independent risk factors for prolonged shedding (50 patients) included hypoxemia [odds ratio (OR) 2.55, 95% confidence interval (1.3-5.1)] and lower diastolic blood pressure [OR 0.94, 95% CI (0.92-0.97)] on admission. Negative PCR tests taken more than 48 h after initiation of treatment had low diagnostic yield. More severe disease, manifested by hypoxemia and lower blood pressure, is associated with prolonged shedding on oseltamivir treatment.

Entities:  

Keywords:  Diagnostic yield; Influenza; Oseltamivir; PCR; Shedding

Mesh:

Substances:

Year:  2017        PMID: 29143145     DOI: 10.1007/s10096-017-3135-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Diagnosis of influenza in the community: relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza.

Authors:  M Zambon; J Hays; A Webster; R Newman; O Keene
Journal:  Arch Intern Med       Date:  2001-09-24

Review 2.  Rapid diagnostic testing for seasonal influenza: an evidence-based review and comparison with unaided clinical diagnosis.

Authors:  Jeffrey J Petrozzino; Cynthia Smith; Mark J Atkinson
Journal:  J Emerg Med       Date:  2010-03-15       Impact factor: 1.484

3.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

4.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Authors:  K G Nicholson; F Y Aoki; A D Osterhaus; S Trottier; O Carewicz; C H Mercier; A Rode; N Kinnersley; P Ward
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

5.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

Authors:  F G Hayden; J J Treanor; R S Fritz; M Lobo; R F Betts; M Miller; N Kinnersley; R G Mills; P Ward; S E Straus
Journal:  JAMA       Date:  1999-10-06       Impact factor: 56.272

6.  Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus.

Authors:  Sophia Ng; Benjamin J Cowling; Vicky J Fang; Kwok Hung Chan; Dennis K M Ip; Calvin K Y Cheng; Timothy M Uyeki; Peter M Houck; J S Malik Peiris; Gabriel M Leung
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

7.  Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.

Authors:  Alicia M Fry; Doli Goswami; Kamrun Nahar; Amina Tahia Sharmin; Mustafizur Rahman; Larisa Gubareva; Tasnim Azim; Joseph Bresee; Stephen P Luby; W Abdullah Brooks
Journal:  Lancet Infect Dis       Date:  2013-11-22       Impact factor: 25.071

8.  Identification of respiratory viruses in adults: nasopharyngeal versus oropharyngeal sampling.

Authors:  David Lieberman; Devora Lieberman; Avi Shimoni; Ayelet Keren-Naus; Rachel Steinberg; Yonat Shemer-Avni
Journal:  J Clin Microbiol       Date:  2009-09-02       Impact factor: 5.948

9.  Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis.

Authors:  Hanah Kim; Mina Hur; Hee-Won Moon; Yeo-Min Yun; Salvatore Di Somma
Journal:  Ann Intensive Care       Date:  2017-03-07       Impact factor: 6.925

10.  The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment.

Authors:  Iris W Li; Ivan F Hung; Kelvin K To; Kwok-Hung Chan; Samson S Y Wong; Jasper F Chan; Vincent C Cheng; Owen T Tsang; Sik-To Lai; Yu-Lung Lau; Kwok-Yung Yuen
Journal:  Chest       Date:  2010-01-08       Impact factor: 9.410

View more
  4 in total

1.  Differential Effects of Influenza Virus NA, HA Head, and HA Stalk Antibodies on Peripheral Blood Leukocyte Gene Expression during Human Infection.

Authors:  Kathie-Anne Walters; Ruoqing Zhu; Michael Welge; Kelsey Scherler; Jae-Keun Park; Zainab Rahil; Hao Wang; Loretta Auvil; Colleen Bushell; Min Young Lee; David Baxter; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Lindsay Czajkowski; Alison Han; Matthew J Memoli; Jeffery K Taubenberger; John C Kash
Journal:  mBio       Date:  2019-05-14       Impact factor: 7.867

2.  Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia.

Authors:  Gerard Moreno; Alejandro Rodríguez; Jordi Sole-Violán; Ignacio Martín-Loeches; Emili Díaz; María Bodí; Luis F Reyes; Josep Gómez; Juan Guardiola; Sandra Trefler; Loreto Vidaur; Elisabet Papiol; Lorenzo Socias; Carolina García-Vidal; Eudald Correig; Judith Marín-Corral; Marcos I Restrepo; Jonathan S Nguyen-Van-Tam; Antoni Torres
Journal:  ERJ Open Res       Date:  2021-03-08

3.  Age-Specific Seasonal Influenza Vaccine Effectiveness against Different Influenza Subtypes in the Hospitalized Population in Lithuania during the 2015-2019 Influenza Seasons.

Authors:  Monika Kuliese; Aukse Mickiene; Ligita Jancoriene; Birute Zablockiene; Giedre Gefenaite
Journal:  Vaccines (Basel)       Date:  2021-05-04

4.  High Expression of IL-36γ in Influenza Patients Regulates Interferon Signaling Pathway and Causes Programmed Cell Death During Influenza Virus Infection.

Authors:  Shuai Liu; Hui Li; Yeming Wang; Haibo Li; Sisi Du; Xiaohui Zou; Xulong Zhang; Bin Cao
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.